

# Prevention of Type I Diabetes in NOD Mice by Adjuvant Immunotherapy

MICHEL W.J. SADELAIN, HUI-YU QIN, JANA LAUZON, AND BHAGIRATH SINGH

**The nonobese diabetic (NOD) mouse is an excellent model of insulin-dependent (type I) human diabetes mellitus. We report that a single injection of complete Freund's adjuvant (CFA) given at an early age (5 wk) prevented the appearance of diabetes and greatly increased the life span of NOD mice without additional therapy. No treated mouse developed hyperglycemia by the age of 12 mo ( $n = 13$ ), whereas all untreated mice died of diabetes before 8 mo of age ( $n = 38$ ). All CFA-treated mice were alive and healthy at 12 mo of age. Some CFA-treated NOD mice that were monitored for long-term survival are still alive with no sign of disease at 18 mo of age ( $n = 5$ ). Administration of CFA resulted in decreased *in vitro* splenic lymphocyte proliferative responses to alloantigen and mitogen. Cell-mixing experiments indicated that antigen-nonspecific inhibitory cells were elicited in the spleen and increased in the bone marrow. These regulatory cells were Thy-1<sup>-</sup> and nonadherent to nylon wool, as has been described for natural suppressor (NS) cells. These data lend support to a relationship between the boosting of endogenous NS activity and the establishment of tolerance to self in the context of autoimmunity. Our results suggest that early nonspecific immunotherapy of genetically predisposed individuals could prevent the development of autoimmune diabetes.**  
*Diabetes* 39:583–89, 1990

**T**he nonobese diabetic (NOD) mouse spontaneously develops an insulin-dependent diabetes mellitus that has many immunological and pathological similarities to human insulin-dependent diabetes (1,2). The autoimmune nature of the disease is suggested by the

lymphocytic infiltration of the islets of Langerhans, preceding the destruction of insulin-producing  $\beta$ -cells (3). By 3–5 wk of age, mononuclear cells infiltrate periductal and perivascular spaces, leading to insulinitis and diabetes within 3–6 mo of age, and by 8 mo, most mice are affected. As in humans, diabetes in NOD mice is multigenic and possibly controlled by three recessive loci, including one that is linked to the major histocompatibility complex (MHC; 4–6). The genetically determined diabetes and insulinitis in NOD mice are dependent on the presence of NOD hematopoietic stem cells, based on data from radiation chimeras (7,8). The disease can be transferred with splenocytes from NOD mice, and both CD4<sup>+</sup> and CD8<sup>+</sup> T-lymphocyte subsets are necessary for this transfer (9–11). Because T lymphocytes may determine the development of diabetes, we investigated the effect of treatments that affect the immune response on the course of disease. In particular, we used adjuvant immunotherapy and found that a single injection of complete Freund's adjuvant (CFA) given at an early age prevents the appearance of diabetes and confers normal life spans to NOD mice without any additional treatment. Adjuvants, in addition to being immunopotentiators, also act on the regulatory arm of the immune system by inducing nonspecific natural effector cells, which in turn may influence the effector T lymphocytes (12–15). Examination of *in vitro* lymphocyte proliferative responses to alloantigen and mitogen revealed profound modifications in the response of adjuvant-treated mice. Both splenic T- and B-lymphocyte responses were significantly reduced. This reduction was associated with the detection of a radioresistant, Thy-1<sup>-</sup>, nylon-wool-nonadherent cell population in the spleen and an increase in natural suppressor (NS) activity in the bone marrow.

## RESEARCH DESIGN AND METHODS

**Mice.** NOD/Alt, BALB/cJ, C57BL/6J, and BALB/cJ  $\times$  C57BL/6J F<sub>1</sub> mice were bred in our facility at the University of Alberta. NOD mice were kindly provided by E. Leiter of Jackson (Bar Harbor, ME) and bred by brother-sister mating. The incidence of diabetes in female mice in our NOD/Alt colony was >95% by 250 days of age (50% of the mice

From the Department of Immunology and the Muttart Diabetes Research and Training Centre, University of Alberta, Edmonton, Alberta, Canada.

Address correspondence and reprint requests to Dr. Bhagirath Singh, Department of Immunology, 8-60 Medical Sciences Building, University of Alberta, Edmonton, Alberta T6G 2H7, Canada.

Received for publication 1 August 1989 and accepted in revised form 4 January 1990.

were hyperglycemic by 150 days of age). All mice were kept under standard housing conditions with filter tops. Mice were randomized and litter matched for this study, and only females were used. Glycemia was monitored weekly with a Glucoscan 2000 glucometer (Lifescan, Mountain View, CA). CFA was purchased from Difco (Detroit, MI).


**Mixed-lymphocyte reaction (MLR).** The primary *in vitro* allogeneic MLR was studied by culturing  $2 \times 10^5$  responder splenocytes with  $8 \times 10^5$  stimulator splenocytes irradiated with 30 Gy from C3H/HeJ or C57BL/10J mice. After 96 h in 8% fetal bovine serum-containing RPMI-1640 medium (Flow, McLean, VA), each well was pulsed with [*methyl*- $^3\text{H}$ ]thymidine (Du Pont-NEN, Boston, MA) for 24 h before harvesting. All cultures were arranged in quadruplicate wells in flat-bottom 96-well Linbro plates (Flow). In cell-mixing experiments,  $2 \times 10^5$  spleen or bone marrow cells were added at the onset of culture (1:1 cell-mixing ratio).

**Mitogen response.** Two-hundred thousand splenocytes per well were cultured for 72 h in the presence of 2.5  $\mu\text{g/ml}$  concanavalin A (ConA; Calbiochem, La Jolla, CA), 10  $\mu\text{g/ml}$  *Escherichia coli*, phenol-extracted lipopolysaccharide (LPS; Sigma, St. Louis, MO), or medium alone to measure background, followed by a 12-h pulse with [*methyl*- $^3\text{H}$ ]thymidine. Cultures were carried out in medium containing 5% fetal bovine serum in flat-bottom 96-well Linbro plates, each culture performed in quadruplicate. In cell-mixing experiments,  $2 \times 10^5$  spleen or bone marrow cells were added at the onset of culture (1:1 mixing ratio) and eventually titrated by adding  $10^5$  or  $5 \times 10^4$  bone marrow cells to  $2 \times 10^5$  responder spleen cells, defining 1:2 and 1:4 bone marrow-spleen mixing ratios, respectively.

**Cellular phenotyping.** Adherence to nylon wool has been described (12). Nonadherent cells were washed once after filtration through the column and counted. Thy-1<sup>+</sup> cells, which accounted for 80% of the nonadherent fraction of normal splenocytes by fluorescence-activated cell sorter analysis (data not shown), were depleted by antibody (Thy-1.2, Du Pont-NEN) and complement (Low-Tox M rabbit complement, Cedarlane, Hornby, Canada) as previously described (12). This treatment removed 80% of the nonadherent cells by trypan blue exclusion and abrogated response to ConA *in vitro*. In some experiments, the cocultured cells were added after *in vitro* exposure to 15 Gy  $\gamma$ -irradiation, establishing that the regulatory function is partly radioresistant. The splenic regulatory cells were characterized in CFA-treated mice 8 days after intraperitoneal administration of 100  $\mu\text{l}$  of adjuvant and concomitantly prepared from normal spleen. All cellular fractions were added to  $2 \times 10^5$  responder cells at the onset of culture at various regulator-responder ratios (2:1, 1:1, 1:2, 1:4).


## RESULTS

**Prevention of development of diabetes with single CFA injection.** To investigate the effect of adjuvant on the development of T-lymphocyte-dependent diabetes in NOD mice, 5-wk-old prediabetic female NOD mice were administered 50  $\mu\text{l}$  CFA as an emulsion in an equal volume of saline in the hind foot pad. A single injection of CFA prevented the development of hyperglycemia (Fig. 1). Serum glucose levels in CFA-treated mice remained  $<10$  mM up to 11 mo after administration of the adjuvant, whereas in



**FIG. 1.** Early adjuvant administration prevents development of hyperglycemia in nonobese diabetic (NOD) mice. NOD mice were given 50  $\mu\text{l}$  complete Freund's adjuvant ( $\diamond$ ,  $n = 5$ ) or an equal volume of saline ( $\bullet$ ,  $n = 5$ ) once only in foot pad at age 35 days, and serum glucose levels were monitored weekly for 10 mo. Mice were killed when glycemia was  $>500$  mg/dl.

control saline-injected mice, hyperglycemia developed as early as 3 mo after birth, usually rising to  $\geq 27.8$  mM within 2–4 wk of onset. All 38 control mice monitored weekly for blood glucose died by 5 mo of age, which is generally the case in our colony, whereas all CFA-treated mice ( $n = 13$ ) were still alive and healthy 1 yr after birth (Fig. 2). Five CFA-treated NOD mice that were monitored for long-term survival are healthy and of normal weight at 18 mo of age with no sign of diabetes. Similar results were obtained when NOD mice were treated with CFA anytime between 4 and 10 wk after birth (data not shown). Histological examination of the pancreas revealed intact islets and insulin-staining  $\beta$ -cells in NOD mice 8 mo after CFA administration, whereas virtually all islets showed varying degrees of mononuclear cell infiltration (insulinitis) and islet destruction in untreated NOD mice after 4 mo of age (data not shown). Islets exhibiting insulinitis but not destruction were also observed. Studies are in progress to assess whether earlier administration of CFA can prevent both insulinitis and diabetes in NOD mice and BB rats. Because of the autoimmune nature of diabetes in NOD mice and the apparent limitation of the destructive potential of the



**FIG. 2.** Early adjuvant administration extends life span of nonobese diabetic mice. Five-week-old mice were given 50  $\mu\text{l}$  of complete Freund's adjuvant (CFA;  $n = 13$ ) in foot pad or no treatment ( $n = 38$ ). Percentage survival is calculated as  $100 \times (\text{number of surviving mice}) \times (\text{initial number of experimental mice})^{-1}$ . All mice that died had confirmed hyperglycemia.

insulinitis resulting from CFA administration, we next investigated the effect of adjuvant administration on the proliferative responses of T lymphocytes.

**Decreased splenic lymphocyte proliferative responses with CFA administration.** T-lymphocyte-mediated responses were examined *in vitro* in the primary allogeneic MLR and mitogen-induced lymphoproliferative responses. The responses of splenocytes from adjuvant-treated mice were compared to the responses of control (saline-injected) age- and sex-matched mice. The primary allogeneic MLR, studied 8 days after CFA administration, was reduced in both NOD mice and age- and sex-matched nondiabetic BALB/cJ  $\times$  C57BL/6J F<sub>1</sub> mice (Fig. 3A). This reduction was maximal 8–10 days after CFA treatment (data not shown). In one of three representative experiments, including three separately treated mice per group, the lymphocyte proliferative response dropped from  $63,520 \pm 4638$  to  $48,568 \pm 2650$  counts/min (cpm) in NOD mice and from  $62,991 \pm 1116$  to  $26,958 \pm 2867$  cpm in nondiabetic mice. Comparable results were obtained in the mitogen-induced proliferation assays with either ConA or LPS to stimulate the lymphocytes (Fig. 3B). To investigate the mechanism of this reduction, cell-mixing experiments were performed to determine whether regulatory cells elicited by adjuvant administration may account for this effect.

**Antigen-nonspecific inhibitory cells in spleen and bone marrow after CFA administration.** To investigate the presence of regulatory cells, spleen cells from CFA-treated or control mice were mixed with syngeneic responder spleen cells from 2-mo-old untreated donors (Fig. 4). Thus, the addition of splenocytes from CFA-treated but not saline-injected mice reduced the primary allogeneic MLR and the mitogen-induced proliferative responses. Cell-mixing experiments are shown at one responder-spleen-test-spleen cellular ratio (1:1). At this mixing ratio, a comparable reduction of the proliferative response in the MLR and the response to LPS and a lesser reduction in the ConA response of NOD spleen cells than that of BALB/cJ  $\times$  C57BL/6J F<sub>1</sub> cells was achieved. Taken together, these data establish that an inhibitory cell population is present in the spleen after CFA administration. Because nonspecific suppressor cells have been suggested to originate in the bone marrow and migrate to the spleen after adjuvant administration (13–15), we also examined the regulatory potential of bone marrow cells. A naturally occurring suppressor activity in the bone marrow inhibits both the MLR and the proliferative response to LPS and is augmented by CFA administration (Fig. 5). Although this increase is apparent in both diabetic and nondiabetic strains, this activity at the basal level is less in NOD mice than in the BALB/cJ  $\times$  C57BL/6J F<sub>1</sub> strain. Approxi-




FIG. 3. Adjuvant administration results in reduced *in vitro* splenic proliferative responses to alloantigen (A) and mitogen (B). sal, Control saline-injected mice; CFA, complete Freund's adjuvant-treated mice. For each group of mice in the mixed-lymphocyte reaction, syngeneic proliferative responses are plotted above anti-C3H/HeJ allogeneic response (left). Mitogen responses are normalized to facilitate comparisons between treatments and mouse strains (nonobese diabetic [NOD] and BALB/cJ  $\times$  C57BL/6J F<sub>1</sub>, [CB6] mice). Control responses (100%) are  $130,280 \pm 4140$  counts/min (cpm) and  $68,267 \pm 5769$  cpm in concanavalin A (ConA) response and  $11,629 \pm 2209$  and  $35,694 \pm 8923$  cpm in lipopolysaccharide (LPS) response in NOD and CB6 mice, respectively. <sup>3</sup>H-TdR, [methyl-<sup>3</sup>H]thymidine. Data are means  $\pm$  SD (3 mice/group).




FIG. 4. Cells that downregulate mixed-lymphocyte reaction (MLR; A) and proliferative response to mitogen (B) are present in spleen after adjuvant administration. In these cell-mixing experiments,  $2 \times 10^5$  responder spleen cells were mixed with  $2 \times 10^5$  syngeneic spleen cells from complete Freund's adjuvant (CFA)-treated or control mice in each culture well (1:1 cell-mixing ratio). Addition of spleen cells from CFA-treated mice resulted in reduction of proliferative response, indicating that natural suppressor activity was present in spleen 8 days after adjuvant administration. Data are normalized to facilitate comparisons. Control responses (100%) are  $46,409 \pm 1213$  and  $32,681 \pm 2419$  counts/min (cpm) in MLR in nonobese diabetic (NOD) and BALB/cJ  $\times$  C57BL/6J F<sub>1</sub> (CB6) mice, respectively, which is not significantly different from response of responder spleen cells alone (data not shown). Responses to concanavalin A (conA) are  $113,860 \pm 4966$  and  $84,651 \pm 5079$  cpm, and responses to lipopolysaccharide (LPS) are  $14,979 \pm 1178$  and  $28,664 \pm 1251$  cpm in NOD and CB6 mice, respectively. <sup>3</sup>H-TdR, [*methyl*-<sup>3</sup>H]thymidine. Data are means  $\pm$  SD.

mately  $20 \times 10^4$  NOD bone marrow cells are necessary to reduce the control lymphoproliferative response by 50%, whereas only  $9 \times 10^4$  cells are required 8 days after CFA administration (Fig. 5B). In nondiabetic BALB/cJ  $\times$  C57BL/6J F<sub>1</sub> mice,  $8 \times 10^4$  marrow cells from untreated mice and only  $4 \times 10^4$  cells after CFA administration are necessary to reduce the response by half. Thus, we conclude from these mixing experiments that NS activity is increased in bone marrow and elicited in spleen after adjuvant administration.

**Mediation of NS activity by nylon-wool-nonadherent Thy-1<sup>-</sup> radioresistant effector cells.** To characterize the effector cells mediating the antigen-nonspecific inhibitory activity that is induced in the spleen after CFA administration, we evaluated the adherence to nylon wool, the presence of surface Thy-1 molecules, and the radioresistance profile of the inhibitory spleen cells. By cell-mixing experiments in the primary allogeneic MLR and the LPS proliferation assays, the regulatory activity resided within the nylon-wool-nonadherent Thy-1<sup>-</sup> fraction (Fig. 6). The addition of nylon-wool-nonadherent Thy-1<sup>-</sup> cells from CFA-treated mice reduced the mean  $\pm$  SD proliferative responses by  $45.9 \pm 9.2\%$  in MLR and  $45.8 \pm 8.7\%$  in LPS stimulation at the 1:1 regulator-responder cell ratio, whereas the addition of identically pre-

pared spleen cells from untreated age- and sex-matched NOD mice resulted in  $11.8 \pm 7.8\%$  reduction in MLR ( $P < 0.001$ ) and  $20.9 \pm 8.2\%$  reduction in LPS stimulation ( $P < 0.001$ ). In our experiments, spleen cells were irradiated (15 Gy) before being added to the culture (Fig. 6), which reduced the inhibitory activity by  $\leq 50\%$  (unpublished observations). The relative suppression measured in both assays was of comparable magnitude at each cell-mixing ratio. We therefore conclude that the NS activity present in the spleen after adjuvant administration is mediated by Thy-1<sup>-</sup> cells (unlike splenic T lymphocytes) and nylon-wool-nonadherent cells (unlike B lymphocytes and macrophages, which tend to stick to the columns).

#### DISCUSSION

We found that a single injection of CFA given at an early prediabetic stage in NOD mice can prevent the development of hyperglycemia and death. Although this was associated with conservation of insulin-producing  $\beta$ -cells, infiltration of the islets with mononuclear cells was not completely eradicated, suggesting that adjuvant therapy acted by reducing  $\beta$ -cell destruction by the mononuclear infiltrate. Prevention of diabetes in these mice was accompanied by the transient global reduction of lymphocyte proliferative responses, the




FIG. 5. Constitutive bone marrow natural suppressor (NS) activity is increased after adjuvant administration. In mixed-lymphocyte reaction (A) at 1:1 bone marrow-spleen cellular ratio, proliferative response is reduced from  $47 \pm 5$  to  $37 \pm 2\%$  when mixed with bone marrow from saline (sal)-treated and complete Freund's adjuvant (CFA)-treated nonobese diabetic (NOD) donors, respectively, and from  $41 \pm 4$  to  $29 \pm 4\%$  in BALB/cJ  $\times$  C57BL/6J F<sub>1</sub> (CB6) counterparts. In proliferative response to lipopolysaccharide (B), bone marrow dilutions are shown to permit semiquantitative appreciation of increase in NS activity. □, NOD mice; ■, CFA-treated NOD mice; ◇, CB6 mice; ◆, CFA-treated CB6 mice. <sup>3</sup>H-TdR, [methyl-<sup>3</sup>H]thymidine. Data are means  $\pm$  SD ( $n = 3$  for each group).

relevance of which is suggested by the ability of T lymphocytes to transfer the disease (9–11). Cell-mixing experiments indicate that this reduction may be attributed at least in part to the induction of regulatory cells in the spleen after adjuvant administration. Several protocols that inhibit T-lymphocyte function have been shown to block the progression of disease in most cases with prolonged therapy (16–23). However, our results differ in one major respect: disease prevention was achieved by a single injection without further therapy, thus establishing that early immunotherapy can affect pathogenic events over a prolonged period. We propose that this effect is conferred by adjuvant alone through the activation of endogenous regulatory cells that can prevent the initiation, amplification, and/or effect of the autoimmune response. This may be particularly so because the mice were treated at an early age, probably at the initial stages of insulinitis, and at the time of first exposure to an islet antigen.

Our data indicate that the reduction of lymphocytic proliferative responses in adjuvant-treated NOD mice is associated with the presence in the spleen of antigen-nonspecific inhibitory cells. Several reports have established that adjuvant administration activates NS activity, ascribed either to suppressor macrophages or nonadherent Thy-1<sup>-</sup> NS cells (for review, see refs. 24–26). NS activity is antigen nonspecific, non-*H-2* restricted, and physiologically present in neonatal spleen (27–31) and adult bone marrow (12–15,32–35). It has been suggested that cells mediating NS activity

migrate from bone marrow to spleen after administration of adjuvants alone without antigen (13–15). We report here that the inhibitory activity is mediated by nylon-wool-nonadherent Thy-1<sup>-</sup> effector cells in the primary allogeneic MLR and the LPS-induced proliferative response. This inhibition operates across MHC barriers (unpublished observations). Therefore, the data suggest that antigen-nonspecific non-*H-2*-restricted Thy-1<sup>-</sup> suppressor (NS) cells are induced in the spleen after adjuvant administration. We have shown elsewhere that this activity is increased in bone marrow and elicited in the spleen after administration of CFA to C57BL/6J and BALB/cJ  $\times$  C57BL/6J F<sub>1</sub> mice, reaching a maximum ~10 days after adjuvant administration, and mediated by Thy-1<sup>-</sup> plastic-nonadherent cells in the bone marrow (12). The data shown here do not exclude the possibility that adjuvant administration may also act independently through other mechanisms involving cytokine or growth factor production by lymphocytes or other cells, intrathymic selection (36), clonal anergy (37), or antigenic expression on target cells.

The lesser reduction of the proliferative responses in the CFA-treated NOD mice than in the CFA-treated nondiabetic mice we studied in parallel may reflect either a less CFA-inducible NS cell reservoir in the NOD mice of our colony or that some NOD lymphocytes are refractory to NS inhibitory




FIG. 6. Phenotypic characterization of nonobese diabetic (NOD) splenic complete Freund's adjuvant (CFA)-induced natural suppressor effector cell in primary allogeneic mixed-lymphocyte reaction (MLR; A) and proliferative response to lipopolysaccharide (LPS; B). Spleen cells from CFA-treated NOD mice were filtered through nylon-wool column (stippled bars) and depleted of Thy-1<sup>+</sup> cells (gray bars). Spleen cells from saline-treated NOD mice were also filtered through nylon-wool column (hatched bars) and depleted of Thy-1<sup>+</sup> cells (black bars). Cells were irradiated (15 Gy) before coculture. Regulatory cells were added at different ratios to fixed number ( $2 \times 10^5$ ) of syngeneic (NOD) responder spleen cells. Results are means  $\pm$  SD of suppression of response achieved in absence of added regulatory cells (17,922  $\pm$  412 counts/min [cpm] in MLR and 129,851  $\pm$  14,919 cpm in LPS assay). Each data point represents 3 mice.

signals. A spontaneous permanent reduction of endogenous NS activity would strongly support a relationship between this immunoregulatory activity and the control of the diabetic phenotype. In the NZB autoimmune mouse strain, a profound deficiency in bone marrow NS activity in vitro has been reported and suggested to play a role in the autoimmune response (38).

NS cells have been suggested to play an important role in the induction of self-tolerance in neonatal mice, the regulation of immune responses, and the success of allogeneic bone marrow transplantation after total lymphoid irradiation (for review, see ref. 25). The administration of adjuvant early in life (or the eventual influence of environmental factors that increase NS activity) may enhance extrathymic mechanisms of tolerance induction to self-antigens by extending and/or amplifying the spontaneously elevated NS activity that characterizes the postnatal period (12,27–31).

Whatever the mechanism of the prevention of diabetes in NOD mice after administration of CFA, this approach provides a simple method for maintaining NOD mice in a disease-free state. Our results establish that early nonspecific immunotherapy in a murine model can prevent the development of diabetes in genetically predisposed individuals. We hope that this approach may also serve as a basis for strategies of preventive therapy in human insulin-dependent diabetes mellitus and perhaps other autoimmune diseases.

#### ACKNOWLEDGMENTS

This work was supported by grants from the Canadian Diabetes Association and the Alberta Heritage Foundation for Medical Research. A preliminary report on this work was presented at the 49th annual meeting of the American Diabetes Association in Detroit, Michigan, June 1989.

We thank Drs. G. Molnar, A. Rabinovitch, and T. Wegmann for helpful discussion.

#### REFERENCES

- Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochimura Y: Breeding of non-obese diabetic strain of mice. *Exp Anim* 29:1–13, 1980
- Kanazawa Y, Kameda K, Sato S, Mori S, Akamura K, Takuku F: Non-obese diabetic mice: immune mechanisms of pancreatic  $\beta$ -cell destruction. *Diabetologia* 27:113–15, 1984
- Miyazaki A, Hanafusa T, Yamada K, Miyagawa J, Nakajima H, Nonaka K, Tarui S: Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic NOD mice: a longitudinal study. *Clin Exp Immunol* 6:622–30, 1985
- Hattori M, Buse JB, Jackson RA, Glimcher L, Dorf ME, Minami H, Makino S, Moriwzki K, Kuzuya H, Imura H, Strauss WM, Seidman JG, Eisenbarth GS: The NOD mouse recessive diabetogenic gene in the major histocompatibility complex. *Science* 231:733–35, 1986
- Wicker LS, Miller BJ, Cooker LZ, McNally SE, Scott S, Mullen Y, Appel MC: Genetic control of diabetes and insulinitis in the non-obese diabetic (NOD) mouse. *J Exp Med* 165:1639–54, 1987
- Prochazka M, Leiter EH, Serreze DV, Coleman DL: Three recessive loci required for insulin-dependent diabetes in non-obese diabetic mice. *Science* 237:286–89, 1987
- Serreze DV, Leiter EH, Worthen SM, Shultz LD: NOD marrow stem cells adoptively transfer diabetes to resistant (NOD  $\times$  NON)<sup>F1</sup> mice. *Diabetes* 37:252–55, 1988
- Wicker LS, Miller BJ, Choi A, Terada M, Mullen Y: Expression of genetically determined diabetes and insulinitis in the NOD mouse at the level of bone marrow-derived cells. *J Exp Med* 167:1801–10, 1988
- Wicker LS, Miller BJ, Mullen Y: Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. *Diabetes* 35:855–60, 1986
- Bendelac A, Carnaud C, Boitard C, Bach JF: Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates: requirement for both L3T4<sup>+</sup> and Ly2<sup>+</sup> T cells. *J Exp Med* 166:823–32, 1987
- Miller B, Appel MC, O'Neil JJ, Wicker LS: Both the Lyt2<sup>+</sup> and L3T4<sup>+</sup> T cell subsets are required for the transfer of diabetes in NOD mice. *J Immunol* 140:52–58, 1988
- Sadelain MWJ, Voralia M, Green DR, Wegmann TG: The role of natural suppressor and natural killer activities in resistance to hemopoietic transplantation in unirradiated recipient mice. *J Immunol* 142:2270–78, 1989
- Bennett JA, Rao SV, Mitchell MS: Systemic BCG activates natural suppressor cells. *Proc Natl Acad Sci USA* 75:5142–44, 1978
- Bennett JA, Mitchell MS: Systemic administration of BCG activates natural suppressor cells in the bone marrow and stimulates their migration into the spleen. In *Neoplasia and Immunity: Experimental and Clinical*. Crispen RG, Ed. Amsterdam, Elsevier/North-Holland, 1980, p. 397–403
- Kato K, Yamamoto KI, Kimura T: Migration of natural suppressor cells from bone marrow to peritoneal cavity by live BCG. *J Immunol* 135:3661–68, 1985
- Ikehara S, Ohtsuki H, Good RA, Asamoto H, Nakamura T, Sekita K, Muso

- E, Tochino Y, Ida T, Kuzuya H, Imura H, Hamashima Y: Prevention of type I diabetes in non-obese diabetic mice by allogeneic bone marrow transplantation. *Proc Natl Acad Sci USA* 82:7743-47, 1985
17. Mori Y, Suko M, Okaidura H, Matsuba I, Tsuruoka A, Sasaki A, Yokoyama H, Tanase T, Shida T, Nishimura H, Terada E, Ikeda Y: Preventive effects of cyclosporin on diabetes in NOD mice. *Diabetologia* 29:244-47, 1986
  18. Toyota T, Satoh J, Oya K, Shintani S, Okano T: Streptococcal preparation (0K-432) inhibits development of type I diabetes in NOD mice. *Diabetes* 35:496-99, 1986
  19. Koike T, Itoh Y, Ishii T, Ito I, Takabayashi K, Maruyama N, Tomioka H, Yoshida S: Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. *Diabetes* 36:539-41, 1987
  20. Wang Y, Hao L, Gill RG, Lafferty KJ: Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent. *Diabetes* 36:535-38, 1987
  21. Shizuru JA, Gregory AK, Chao CT, Fathman CG: Islet allograft survival after a single course of treatment of recipient with antibody to L3T4. *Science* 237:278-80, 1987
  22. Kelley VE, Gaulton GN, Hattori M, Ikegami H, Eisenbarth G, Strom TB: Anti-interleukin 2 receptor antibody suppresses murine diabetic insulinitis and lupus nephritis. *J Immunol* 140:59-61, 1988
  23. Boitard C, Bendelac A, Richard MF, Carnaud C, Bach JF: Prevention of diabetes in non-obese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cells. *Proc Natl Acad Sci USA* 85:9719-23, 1988
  24. Holden TH, Herberman RB: Suppression of immune responses by macrophages. In *The Modulation of Immunity*. Mitchell MS, Ed. New York, Pergamon, 1985, p. 51-69
  25. Strober S: Natural suppressor (NS) cells, neonatal tolerance and total lymphoid irradiation: exploring obscure relationships. *Annu Rev Immunol* 2:219-38, 1984
  26. Holda JH, Maier T, Claman HN: Murine graft-vs.-host disease across minor barriers: immunosuppressive effects of natural suppressor cells. *Immunol Rev* 88:87-106, 1985
  27. Argyris BF: Suppressor activity in the spleen of neonatal mice. *Cell Immunol* 36:354-62, 1978
  28. Rodrigues G, Anderson G, Wigzell H, Peck AB: Non-T cell nature of the naturally occurring, spleen-associated suppressor cells present in the newborn mouse. *Eur J Immunol* 9:737-46, 1979
  29. Piguet PF, Irle C, Vassalli P: Immunosuppressor cells from newborn spleen are macrophages differentiating in vitro from monoblastic precursors. *Eur J Immunol* 11:56-61, 1981
  30. Snyder DS, Lu CY, Unanue ER: Control of macrophage Ia expression in neonatal mice: role of a splenic suppressor cell. *J Immunol* 128:1458-65, 1982
  31. Okada S, Strober S: Spleen cells from adult mice given total lymphoid irradiation (TLI) or from newborn mice have similar regulatory effects in the mixed leukocyte reaction (MLR). II. Generation of antigen-specific suppressor cells in the MLR after the addition of spleen cells from newborn mice. *J Immunol* 129:1892-97, 1982
  32. Duwe AK, Singhal SK: The immunosuppressive role of bone marrow. I. Suppression of the induction of antibody responses to T-dependent and T-independent antigens by cells in the bone marrow. *Cell Immunol* 43:362-71, 1979
  33. Dorschkind K, Klimpel GR, Rosse C: Natural regulatory cells in murine bone marrow: inhibition of in vitro proliferative and cytotoxic responses to alloantigens. *J Immunol* 124:2584-88, 1980
  34. Corvese JS, Levy EM, Bennett M, Cooperband SR: Inhibition of an in vitro antibody response by a suppressor cell in normal bone marrow. *Cell Immunol* 49:293-306, 1980
  35. May RD, Slavin S, Vitetta ES: A partial characterization of suppressor cells in the spleen of mice conditioned with fractionated total lymphoid irradiation. *J Immunol* 131:1108-14, 1983
  36. White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P: The V $\beta$ -specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. *Cell* 56:27-35, 1989
  37. Rammensee HG, Kroschewski R, Frangoulis B: Clonal energy induced in mature V $\beta$ 6<sup>+</sup> T lymphocytes on immunizing Mls-1<sup>b</sup> mice with Mls-1<sup>a</sup> expressing cells. *Nature (Lond)* 339:541-44, 1989
  38. Smythe DK, Atkinson MJ, Salfran DC, McCain GA, Singhal SK: Regulation of the anti-DNA antibody response by bone marrow-derived natural suppressor cells and their factor BDSF: evidence for deficiency of natural suppressor activity in NZB and NZB/W mice. *J Immunol*. In press